Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 9:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 153 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Lopinavir/ritonavir Clear all

Conditions: HIV Infection
Interventions: MEMS cap; Device
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections, Malaria
Interventions: Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 60 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV, AIDS
Interventions: Kaletra (drug); Drug
Lead sponsor: Lampiris, Harry W., M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: Human Immunodeficiency Virus-1
Interventions: maraviroc; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 16 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 27
States / cities: Los Angeles, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 16 more

Conditions: Healthy
Interventions: Gingko Biloba, Echinacea purpurea, Panax ginseng; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions: Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: HIV Infections, AIDS-Related Opportunistic Infections
Interventions: Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 43
States / cities: Sacramento, California • San Diego, California • San Francisco, California + 24 more

Conditions: HIV Infections
Interventions: Atazanavir+ritonavir, Lopinavir+ritonavir; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 52
States / cities: Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more

Conditions: HIV Infections
Interventions: Kaletra + Isentress, Pre-study antiretroviral regimen; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: GSK1349572; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: HIV Infections
Interventions: ARV regimen chosen by treating physician; Drug
Lead sponsor: Kristine Patterson, MD; Other
Eligibility: 19 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet, LPV; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Phoenix, Arizona • Laguna Beach, California • Washington D.C., District of Columbia + 5 more

Conditions: Human Immunodeficiency Virus Infections
Interventions: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs); Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: HIV
Interventions: Lopinavir/Ritonavir; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19, SARS-CoV-2
Interventions: Ascorbic Acid, Hydroxychloroquine Sulfate, Azithromycin, Folic Acid, Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 289 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 6
States / cities: Chicago, Illinois • New Orleans, Louisiana • Boston, Massachusetts + 2 more

Conditions: Human Immunodeficiency Virus Type 1
Interventions: D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF; Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 38
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Emtricitabine, Stavudine; Drug
Lead sponsor: Triangle Pharmaceuticals; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more

Conditions: HIV Infections
Interventions: Lopinavir/ritonavir, Ritonavir; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Abacavir sulfate, Nevirapine, Lamivudine, Stavudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 23
States / cities: Los Angeles, California • Denver, Colorado • Honolulu, Hawaii + 12 more

Conditions: HIV Infections
Interventions: Lopinavir/Ritonavir, Nelfinavir mesylate, Lamivudine, Stavudine; Drug
Lead sponsor: Abbott; Industry
Eligibility: 12 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 42
States / cities: Beverly Hills, California • Fountain Valley, California • Los Angeles, California + 31 more

Conditions: HIV Infections
Interventions: EVG, RTV, ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: Not listed
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 47
States / cities: Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more

Conditions: HIV Infections
Interventions: LPV/r; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections, Lipodystrophy, Wasting Disease
Interventions: Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 25
States / cities: Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more

Search by objective public record fields.

Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen

Drug Interaction Study Between Antimalarial and Anti-HIV Medications

High Dose Ritonavir/Lopinavir Liquid Formulation in Salvage Therapy for Protease Inhibitor Resistant HIV Disease

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers

CiPA Phase 1 ECG Biomarker Validation Study

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

Kaletra-isentress Treatment Evaluation

GSK1349572 Drug Interaction Study With Protease Inhibitors

Sex, Aging and Antiretroviral Pharmacokinetics

BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada

Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects

Pilot Study of Effect of Kaletra on CD4 Response in HIV Positive (+) Patients With Viral Suppression KIMBO Study

Treatment for COVID-19 in High-Risk Adult Outpatients

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors

Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

Kaletra Sex/Gender Pharmacokinetics (PK) Study

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients